Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

A global first-in-human study of PM577a is underway to evaluate its safety, tolerability and initial clinical efficacy. The therapy is designed as a one-time treatment to correct the H1069Q mutation in ATP7B, identified as the most prevalent Wilson disease-causing mutation in North America and Europe; no study results are reported.